Contemporary efficacy of warfarin for afib-related stroke prevention

As new antithrombotics become available, contemporary efficacy of warfarin to reduce afib-related stroke is needed to determine which agents are best for which patients. In this meta-analysis of 8 large RCTs, time spent in therapeutic range was 55% to 68%, and annual risk of stroke was 1.7% per year (higher with higher CHADS2 scores) and risk of bleeding ranged from 1.4% to 3.4% per year. The contemporary statistics can help physicians and patients make the best anticoagulation decisions for stroke prevention (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment